Food allergy is an immune system reaction to certain foods, potentially causing severe, life-threatening symptoms. It affects around 220 million people globally, with a significant unmet need for effective treatments beyond avoidance strategies and emergency epinephrine. Current therapeutic options remain limited, driving research into innovative drugs and therapeutics. Emerging drug candidates, including biologics targeting immune modulation, show promise in enhancing patient outcomes. This evolving landscape highlights the potential for more effective food allergy therapeutic products in the coming years.
Major companies involved in the food allergy pipeline drugs market include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, and others.
Leading drugs currently in the pipeline include Ligelizumab, Remibrutinib, IGNX001, and others.
The rising prevalence of food allergies, high unmet clinical needs, and advancements in immunotherapy are driving growth in the food allergy drug pipeline.
The Food Allergy Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into food allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for food allergy. The food allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The food allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with food allergy treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to food allergy.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Food allergy is an immune system reaction to certain foods, triggering symptoms like hives, swelling, digestive issues, or even anaphylaxis. It occurs when the body mistakenly identifies a harmless food as a threat. Common allergens include peanuts, tree nuts, milk, eggs, soy, wheat, fish, and shellfish.
Food allergy management focuses on allergen avoidance and symptom control. Antihistamines can relieve mild reactions, while epinephrine is essential for anaphylaxis. Oral immunotherapy is an emerging treatment to build tolerance to allergens. Regular consultations with an allergist, accurate food labeling checks, and carrying emergency medication are vital steps to ensure safety and prevent severe allergic reactions.
Food allergy affects approximately 220 million people globally, with significant regional variations. In the United States, it impacts up to 8% of children and 10% of adults. In the United Kingdom, 6% of adults, or 2.4 million individuals, have clinically confirmed food allergies. In Japan, prevalence rates reach 10% in infants, 5% in young children, and 4.5% in school children.
This section of the report covers the analysis of food allergy drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total food allergy clinical trials.
The drug molecule categories covered under the food allergy pipeline analysis include monoclonal antibodies, biologics, small molecules, peptides, immunotherapies, and others. The food allergy report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for food allergy.
The EMR report for the food allergy drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed food allergy therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in food allergy clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for food allergy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of food allergy drug candidates.
Ligelizumab, sponsored by Novartis Pharmaceuticals, is undergoing a Phase III extension study to evaluate its long-term safety and efficacy in food allergy treatment. This next-generation anti-IgE monoclonal antibody blocks the IgE/FcεRI pathway, reducing allergic inflammation. The study will assess symptom resolution, quality of life improvements, and the drug’s potential for long-term, self-administered treatment.
Remibrutinib, an oral BTK inhibitor, aims to reduce allergic reactions by modulating immune responses. Novartis Pharmaceuticals is conducting a Phase II study to evaluate the efficacy, safety, and tolerability of Remibrutinib in adults with peanut allergies. The study will assess participants' ability to tolerate increasing peanut protein doses after one month of treatment with varying drug doses.
IGNX001 is an IgG4 monoclonal antibody developed by IgGenix Australia Pty Ltd. It is currently undergoing a Phase I clinical trial for peanut allergy. The study aims to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. IGNX001 has demonstrated potent inhibition of peanut-induced mast cell degranulation, positioning it as a promising food allergy therapeutic product for improved allergy management.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Food Allergy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for food allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into food allergy collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share